White crystalline powder. Odorless to practically odorless.
Registry Numbers and Inventories.
Melting point, °C
Solubility in water
Hazards and Protection.
Anileridine usp and anileridine hydrochloride usp - preserve in tight, light-resistant containers. Anileridine injection usp - preserve in single dose or in multiple-dose containers, preferably of type i glass, protected from light.
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stable in air anileridine dihydrochloride oxidizes and darkens both in air and on exposure to light solutions are stable @ pH 3.5 and below; @ pH 4 and higher insol free base is precipitated.
Strong oxidizing agents.
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.
Abnormally low blood pressure and elevated body temperature or reduced body temperature may occur. lethargy and coma associated with pinpoint pupils occur frequently. Coma, seizures, myoclonic reactions, and spongiform encephalopathy and myelopathy have been reported in abusers of opioids.
Delayed gastric emptying may result in cyclic coma.
Respiratory depression leading to respiratory arrest, pulmonary edema, hypoxia, bronchospasm, acute asthma, bullous pulmonary damage, and pneumonitis have occurred and abuse of opioids.
Rash has been reported during therapeutic use of opioid narcotics. Seborrhea may be seen following mptp overdoses. Scleroderma following heroin abuse has been reported and may be linked to talc mixed with heroin.
Pupils are usually pinpoint but may be dilated in the presence of severe acidosis, hypoxia, or respiratory depression.
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
Inhalation of opioids may result from drug abuse of persons crushing and snorting tablets. Clinical effects and treatment is based on the oral route of exposure.
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.